Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Comprehensive mutational analysis of five major clinical ß-lactamases to elucidate evolvability and family-level trends

EF 2022-23

Résumé
Antimicrobial resistance (AMR) continues to be a growing health concern—by 2050, AMR infections are projected to cost 396,000 Canadian lives and $388 billion to the Canadian economy. Among pathogenic bacteria, ?-lactamases (BLs) are a commonly observed resistance mechanism against ?-lactams, one of the most widely used antibiotics. These enzymes display great diversity and evolve rapidly in hospitals, hindering our ability to predict and combat ?-lactam resistance. Currently, we lack understanding of the effects of BL diversity (sequence differences or mutations) on their efficacy against ?-lactams and BL inhibitors (BLIs). Furthermore, most studies on BLs are conducted in model organisms, and hence we lack knowledge on the evolutionary potential in real pathogens. Addressing these knowledge gaps will improve both our ability to predict future “variants of concern” and create effective programs to combat resistance. Hence, I propose to investigate the mechanisms of ?-lactam and BLI resistance in BLs as well as their evolutionary potential in clinical pathogens. I will investigate five clinical BL representatives, generating and measuring the effects of a comprehensive set of mutational variants (~6,000) for each BL against a panel of representative ?-lactams and BLIs. Mapping mutational effects to the 3D protein structures will reveal critical residues involved in ?-lactam and BLI recognition. I will also study the adaptability of BL mutants to two clinical pathogens, revealing the potential for these enzymes to disseminate among bacteria prevalent in hospitals. This comprehensive dataset is expected to aid in combatting AMR, by informing future drug development and guiding programs to circumvent predicted evolutionary paths towards new and higher resistance.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486000
Name
Lee Dongkyu
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comprehensive mutational analysis of five major clinical ß-lactamases to elucidate evolvability and family-level trends
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antimicrobial Resistance; Deep Mutational Scanning; Gram-Negative Pathogen; Host Adaptability; Inhibitor Escape; Metallo-ß-Lactamase; Mutagenesis; Serine-ß-Lactamase; ß-Lactam Antibiotic; ß-Lactamase Inhibitor
Abstract
Antimicrobial resistance (AMR) continues to be a growing health concern—by 2050, AMR infections are projected to cost 396,000 Canadian lives and $388 billion to the Canadian economy. Among pathogenic bacteria, ?-lactamases (BLs) are a commonly observed resistance mechanism against ?-lactams, one of the most widely used antibiotics. These enzymes display great diversity and evolve rapidly in hospitals, hindering our ability to predict and combat ?-lactam resistance. Currently, we lack understanding of the effects of BL diversity (sequence differences or mutations) on their efficacy against ?-lactams and BL inhibitors (BLIs). Furthermore, most studies on BLs are conducted in model organisms, and hence we lack knowledge on the evolutionary potential in real pathogens. Addressing these knowledge gaps will improve both our ability to predict future “variants of concern” and create effective programs to combat resistance. Hence, I propose to investigate the mechanisms of ?-lactam and BLI resistance in BLs as well as their evolutionary potential in clinical pathogens. I will investigate five clinical BL representatives, generating and measuring the effects of a comprehensive set of mutational variants (~6,000) for each BL against a panel of representative ?-lactams and BLIs. Mapping mutational effects to the 3D protein structures will reveal critical residues involved in ?-lactam and BLI recognition. I will also study the adaptability of BL mutants to two clinical pathogens, revealing the potential for these enzymes to disseminate among bacteria prevalent in hospitals. This comprehensive dataset is expected to aid in combatting AMR, by informing future drug development and guiding programs to circumvent predicted evolutionary paths towards new and higher resistance.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lee, Dongkyu
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~